Celera Genomics, Medarex to develop therapeutic antibodies for treatment of cancer

By Lisa Kerner

Charlotte, N.C., June 22 - Celera Genomics and Medarex, Inc. formed a strategic collaboration to develop fully human antibodies for the treatment of multiple cancer indications.

Under the collaboration, the companies will jointly select targets from Celera's portfolio of novel cancer targets, while Medarex will generate fully human monoclonal antibodies against the targets using its UltiMAb Human Antibody Development System.

Both companies will jointly conduct initial validation studies, but will alternate the selection of antigen-antibody research programs for independent commercialization. The agreement calls for milestone and royalty payments from the selecting company to the other party.

Other financial terms of the agreement were not disclosed, according to a company news release.

Celera, an Applera Corp. business based in Rockville, Md., uses proprietary genomics and proteomics discovery platforms to develop molecular diagnostic products and to identify and validate novel drug targets.

Princeton, N.J.-based Medarex develops fully human antibody-based therapeutics to treat cancer, inflammation, autoimmune disorders and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.